North America Prescription Drugs Market Size and Forecast (2021 - 2031), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Branded and Generics), Drug Type (Small Molecule and Biologics and Biosimilar), Therapeutic Area (Oncology, Cardiovascular Diseases, Neurological Diseases, Metabolic Diseases, Respiratory Diseases, Immunology, and Others), Route of Administration (Oral, Injectable, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
The North America Prescription Drugs Market is projected to grow significantly, reaching an estimated US$ 1,157.0 billion by 2031, up from US$ 707.7 billion in 2024, reflecting a compound annual growth rate (CAGR) of 7.3% from 2025 to 2031. This growth is primarily driven by several key factors, including an aging population, advancements in pharmaceutical research, and a robust healthcare infrastructure.
One of the most significant contributors to the market's expansion is the aging population in North America. As the baby boomer generation ages, there is a notable increase in the prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer. This demographic shift is leading to a higher demand for prescription medications, as older adults typically require more healthcare services and medications to manage their health conditions.
In addition to demographic changes, advancements in pharmaceutical research and biotechnology are playing a crucial role in market growth. Innovations in drug development, particularly in biologics and personalized medicine, have broadened treatment options, improving both efficacy and safety. The introduction of novel therapies for previously untreatable conditions has further stimulated market demand, as patients seek effective treatments for complex health issues.
The strong healthcare infrastructure in North America also supports market growth. Significant investments in healthcare facilities, insurance coverage, and pharmaceutical distribution networks ensure that prescription medications are widely available. Increased patient awareness regarding disease management and treatment options has led to higher consumption of prescription drugs. Regulatory support from agencies like the US Food and Drug Administration (FDA) facilitates quicker approval processes for innovative drugs, allowing for faster market entry and increased availability of new therapies. Furthermore, government initiatives aimed at expanding healthcare coverage, such as the Affordable Care Act in the US, have improved access to prescription drugs for a larger segment of the population.
The rise in lifestyle-related diseases and the growing prevalence of mental health disorders have also contributed to sustained demand for therapeutic drugs. The COVID-19 pandemic underscored the importance of pharmaceutical interventions, leading to accelerated investments in drug development and distribution. As a result, the market is expected to continue its upward trajectory, driven by the increasing need for effective treatments.
Market segmentation reveals that the North America Prescription Drugs Market can be categorized by product type, drug type, therapeutic area, route of administration, and distribution channel. In 2024, the market was primarily segmented into branded and generic drugs, with branded drugs holding the largest market share. By drug type, small molecules dominated the market, while oncology emerged as the leading therapeutic area. The route of administration analysis indicated that oral medications were the most commonly prescribed, and hospital pharmacies accounted for the largest distribution channel.
The increasing prevalence of chronic conditions is a significant factor influencing the market. According to the World Health Organization (WHO), chronic lifestyle diseases are expected to rise by 57% by 2026. Urbanization and sedentary lifestyles contribute to the growing incidence of conditions such as diabetes and cardiovascular diseases. Diabetes, in particular, is a major global health concern, with the International Diabetes Federation (IDF) estimating that the number of adults living with diabetes will increase from 589 million in 2024 to 853 million by 2050.
Chronic conditions such as multiple sclerosis, Crohn's disease, and cardiovascular disorders necessitate long-term medication management, which often involves multiple prescriptions and advanced therapies. The nature of these chronic diseases typically requires the use of specialty drugs, which are often more expensive and generate higher revenues for pharmaceutical companies. The unmet clinical needs of patients with rare diseases also drive investment in research and development, further propelling the prescription drugs market.
Geographically, the North America Prescription Drugs Market is segmented into the United States, Canada, and Mexico, with the United States holding the largest market share in 2024. The demand for prescription medications is particularly high due to the prevalence of chronic conditions such as cancer, heart disease, and diabetes. Heart disease remains the leading cause of death in the US, with nearly one million Americans dying from cardiovascular disease annually. The American Heart Association reports that nearly half of all adults in the US have some form of cardiovascular disease, and this number is expected to rise significantly by 2035.
Cancer is another critical area of concern, with approximately 1.9 million new cases diagnosed in the US in 2022. The demand for innovative treatment options is increasing, with advancements in oncology, immunology, and gene therapies expanding the range of available treatments. Despite these advancements, prescription drug spending continues to rise, highlighting the ongoing need for effective and accessible medications.
Key players in the Prescription Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi SA, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, and Eli Lilly and Co. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and meet the growing demand for prescription drugs.
One of the most significant contributors to the market's expansion is the aging population in North America. As the baby boomer generation ages, there is a notable increase in the prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer. This demographic shift is leading to a higher demand for prescription medications, as older adults typically require more healthcare services and medications to manage their health conditions.
In addition to demographic changes, advancements in pharmaceutical research and biotechnology are playing a crucial role in market growth. Innovations in drug development, particularly in biologics and personalized medicine, have broadened treatment options, improving both efficacy and safety. The introduction of novel therapies for previously untreatable conditions has further stimulated market demand, as patients seek effective treatments for complex health issues.
The strong healthcare infrastructure in North America also supports market growth. Significant investments in healthcare facilities, insurance coverage, and pharmaceutical distribution networks ensure that prescription medications are widely available. Increased patient awareness regarding disease management and treatment options has led to higher consumption of prescription drugs. Regulatory support from agencies like the US Food and Drug Administration (FDA) facilitates quicker approval processes for innovative drugs, allowing for faster market entry and increased availability of new therapies. Furthermore, government initiatives aimed at expanding healthcare coverage, such as the Affordable Care Act in the US, have improved access to prescription drugs for a larger segment of the population.
The rise in lifestyle-related diseases and the growing prevalence of mental health disorders have also contributed to sustained demand for therapeutic drugs. The COVID-19 pandemic underscored the importance of pharmaceutical interventions, leading to accelerated investments in drug development and distribution. As a result, the market is expected to continue its upward trajectory, driven by the increasing need for effective treatments.
Market segmentation reveals that the North America Prescription Drugs Market can be categorized by product type, drug type, therapeutic area, route of administration, and distribution channel. In 2024, the market was primarily segmented into branded and generic drugs, with branded drugs holding the largest market share. By drug type, small molecules dominated the market, while oncology emerged as the leading therapeutic area. The route of administration analysis indicated that oral medications were the most commonly prescribed, and hospital pharmacies accounted for the largest distribution channel.
The increasing prevalence of chronic conditions is a significant factor influencing the market. According to the World Health Organization (WHO), chronic lifestyle diseases are expected to rise by 57% by 2026. Urbanization and sedentary lifestyles contribute to the growing incidence of conditions such as diabetes and cardiovascular diseases. Diabetes, in particular, is a major global health concern, with the International Diabetes Federation (IDF) estimating that the number of adults living with diabetes will increase from 589 million in 2024 to 853 million by 2050.
Chronic conditions such as multiple sclerosis, Crohn's disease, and cardiovascular disorders necessitate long-term medication management, which often involves multiple prescriptions and advanced therapies. The nature of these chronic diseases typically requires the use of specialty drugs, which are often more expensive and generate higher revenues for pharmaceutical companies. The unmet clinical needs of patients with rare diseases also drive investment in research and development, further propelling the prescription drugs market.
Geographically, the North America Prescription Drugs Market is segmented into the United States, Canada, and Mexico, with the United States holding the largest market share in 2024. The demand for prescription medications is particularly high due to the prevalence of chronic conditions such as cancer, heart disease, and diabetes. Heart disease remains the leading cause of death in the US, with nearly one million Americans dying from cardiovascular disease annually. The American Heart Association reports that nearly half of all adults in the US have some form of cardiovascular disease, and this number is expected to rise significantly by 2035.
Cancer is another critical area of concern, with approximately 1.9 million new cases diagnosed in the US in 2022. The demand for innovative treatment options is increasing, with advancements in oncology, immunology, and gene therapies expanding the range of available treatments. Despite these advancements, prescription drug spending continues to rise, highlighting the ongoing need for effective and accessible medications.
Key players in the Prescription Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi SA, Johnson & Johnson, AstraZeneca Plc, AbbVie Inc, and Eli Lilly and Co. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and meet the growing demand for prescription drugs.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. PRESCRIPTION DRUGS MARKET LANDSCAPE
4.1 PEST Analysis
5. NORTH AMERICA PRESCRIPTION DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. PRESCRIPTION DRUGS MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Prescription Drugs Market Revenue (US$ Billion), 2024 - 2031
6.2 North America Prescription Drugs Market Forecast and Analysis
7. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Branded
7.1.1 Overview
7.1.2 Branded: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
7.2 Generics
7.2.1 Overview
7.2.2 Generics: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
8. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY DRUG TYPE
8.1 Small Molecule
8.1.1 Overview
8.1.2 Small Molecule: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
8.2 Biologics and Biosimilar
8.2.1 Overview
8.2.2 Biologics and Biosimilar: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.2 Cardiovascular Diseases
9.2.1 Overview
9.2.2 Cardiovascular Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.3 Neurological Diseases
9.3.1 Overview
9.3.2 Neurological Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.4 Metabolic Diseases
9.4.1 Overview
9.4.2 Metabolic Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.5 Respiratory Diseases
9.5.1 Overview
9.5.2 Respiratory Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.6 Immunology
9.6.1 Overview
9.6.2 Immunology: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.7 Others
9.7.1 Overview
9.7.2 Others: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
10.1 Oral
10.1.1 Overview
10.1.2 Oral: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.2 Injectable
10.2.1 Overview
10.2.2 Injectable: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.3 Topical
10.3.1 Overview
10.3.2 Topical: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.4 Others
10.4.1 Overview
10.4.2 Others: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12. NORTH AMERICA PRESCRIPTION DRUGS MARKET - COUNTRY ANALYSIS
12.1 North America
12.1.1 North America Prescription Drugs Market Revenue and Forecast and Analysis - by Country
12.1.1.1 North America Prescription Drugs Market Revenue and Forecast and Analysis - by Country
12.1.2.2 United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.1.2.2.1 United States: North America Prescription Drugs Market Share - by Product Type
12.1.2.2.2 United States: North America Prescription Drugs Market Share - by Drug Type
12.1.2.2.3 United States: North America Prescription Drugs Market Share - by Therapeutic Area
12.1.2.2.4 United States: North America Prescription Drugs Market Share - by Route Of Administration
12.1.2.2.5 United States: North America Prescription Drugs Market Share - by Distribution Channel
12.2.3.3 Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.2.3.3.1 Canada: North America Prescription Drugs Market Share - by Product Type
12.2.3.3.2 Canada: North America Prescription Drugs Market Share - by Drug Type
12.2.3.3.3 Canada: North America Prescription Drugs Market Share - by Therapeutic Area
12.2.3.3.4 Canada: North America Prescription Drugs Market Share - by Route Of Administration
12.2.3.3.5 Canada: North America Prescription Drugs Market Share - by Distribution Channel
12.3.4.4 Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.3.4.4.1 Mexico: North America Prescription Drugs Market Share - by Product Type
12.3.4.4.2 Mexico: North America Prescription Drugs Market Share - by Drug Type
12.3.4.4.3 Mexico: North America Prescription Drugs Market Share - by Therapeutic Area
12.3.4.4.4 Mexico: North America Prescription Drugs Market Share - by Route Of Administration
12.3.4.4.5 Mexico: North America Prescription Drugs Market Share - by Distribution Channel
13 COMPETITIVE LANDSCAPE
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning & Concentration
14 INDUSTRY LANDSCAPE
14.1 Overview
14.2 New Product Development
14.3 Merger and Acquisition
14.4 Other Strategic Developments
15 COMPANY PROFILES
15.1 GSK Plc
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 F. Hoffmann-La Roche Ltd
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Pfizer Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Merck & Co Inc
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Teva Pharmaceutical Industries Ltd
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Novartis AG
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Sanofi SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Johnson & Johnson
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 AstraZeneca Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 AbbVie Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 Eli Lilly and Co
15.11.1 Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 ESTEVE
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
16. APPENDIX
16.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. PRESCRIPTION DRUGS MARKET LANDSCAPE
4.1 PEST Analysis
5. NORTH AMERICA PRESCRIPTION DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. PRESCRIPTION DRUGS MARKET - NORTH AMERICA MARKET ANALYSIS
6.1 North America Prescription Drugs Market Revenue (US$ Billion), 2024 - 2031
6.2 North America Prescription Drugs Market Forecast and Analysis
7. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
7.1 Branded
7.1.1 Overview
7.1.2 Branded: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
7.2 Generics
7.2.1 Overview
7.2.2 Generics: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
8. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY DRUG TYPE
8.1 Small Molecule
8.1.1 Overview
8.1.2 Small Molecule: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
8.2 Biologics and Biosimilar
8.2.1 Overview
8.2.2 Biologics and Biosimilar: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY THERAPEUTIC AREA
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.2 Cardiovascular Diseases
9.2.1 Overview
9.2.2 Cardiovascular Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.3 Neurological Diseases
9.3.1 Overview
9.3.2 Neurological Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.4 Metabolic Diseases
9.4.1 Overview
9.4.2 Metabolic Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.5 Respiratory Diseases
9.5.1 Overview
9.5.2 Respiratory Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.6 Immunology
9.6.1 Overview
9.6.2 Immunology: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
9.7 Others
9.7.1 Overview
9.7.2 Others: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
10.1 Oral
10.1.1 Overview
10.1.2 Oral: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.2 Injectable
10.2.1 Overview
10.2.2 Injectable: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.3 Topical
10.3.1 Overview
10.3.2 Topical: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
10.4 Others
10.4.1 Overview
10.4.2 Others: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11. NORTH AMERICA PRESCRIPTION DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
11.1 Hospital Pharmacies
11.1.1 Overview
11.1.2 Hospital Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11.2 Retail Pharmacies
11.2.1 Overview
11.2.2 Retail Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
11.3 Online Pharmacies
11.3.1 Overview
11.3.2 Online Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12. NORTH AMERICA PRESCRIPTION DRUGS MARKET - COUNTRY ANALYSIS
12.1 North America
12.1.1 North America Prescription Drugs Market Revenue and Forecast and Analysis - by Country
12.1.1.1 North America Prescription Drugs Market Revenue and Forecast and Analysis - by Country
12.1.2.2 United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.1.2.2.1 United States: North America Prescription Drugs Market Share - by Product Type
12.1.2.2.2 United States: North America Prescription Drugs Market Share - by Drug Type
12.1.2.2.3 United States: North America Prescription Drugs Market Share - by Therapeutic Area
12.1.2.2.4 United States: North America Prescription Drugs Market Share - by Route Of Administration
12.1.2.2.5 United States: North America Prescription Drugs Market Share - by Distribution Channel
12.2.3.3 Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.2.3.3.1 Canada: North America Prescription Drugs Market Share - by Product Type
12.2.3.3.2 Canada: North America Prescription Drugs Market Share - by Drug Type
12.2.3.3.3 Canada: North America Prescription Drugs Market Share - by Therapeutic Area
12.2.3.3.4 Canada: North America Prescription Drugs Market Share - by Route Of Administration
12.2.3.3.5 Canada: North America Prescription Drugs Market Share - by Distribution Channel
12.3.4.4 Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
12.3.4.4.1 Mexico: North America Prescription Drugs Market Share - by Product Type
12.3.4.4.2 Mexico: North America Prescription Drugs Market Share - by Drug Type
12.3.4.4.3 Mexico: North America Prescription Drugs Market Share - by Therapeutic Area
12.3.4.4.4 Mexico: North America Prescription Drugs Market Share - by Route Of Administration
12.3.4.4.5 Mexico: North America Prescription Drugs Market Share - by Distribution Channel
13 COMPETITIVE LANDSCAPE
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning & Concentration
14 INDUSTRY LANDSCAPE
14.1 Overview
14.2 New Product Development
14.3 Merger and Acquisition
14.4 Other Strategic Developments
15 COMPANY PROFILES
15.1 GSK Plc
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 F. Hoffmann-La Roche Ltd
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Pfizer Inc
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Merck & Co Inc
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Teva Pharmaceutical Industries Ltd
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Novartis AG
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Sanofi SA
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Johnson & Johnson
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 AstraZeneca Plc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 AbbVie Inc
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 Eli Lilly and Co
15.11.1 Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 ESTEVE
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
16. APPENDIX
16.1 About The Insight Partners
LIST OF TABLES
Table 1. North America Prescription Drugs Market Segmentation
Table 3. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Table 4. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 5. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 6. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 7. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 8. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 9. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Country
Table 10. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 11. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 12. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 13. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 14. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 15. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 16. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 17. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 18. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 19. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 20. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 21. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 22. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 23. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 24. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 25. Heat Map Analysis by Key Players
Table 1. North America Prescription Drugs Market Segmentation
Table 3. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Table 4. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 5. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 6. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 7. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 8. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 9. North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Country
Table 10. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 11. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 12. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 13. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 14. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 15. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 16. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 17. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 18. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 19. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 20. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Product Type
Table 21. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Drug Type
Table 22. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Therapeutic Area
Table 23. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Route Of Administration
Table 24. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion) - by Distribution Channel
Table 25. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. North America Prescription Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. North America Prescription Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Prescription Drugs Market Revenue (US$ Billion), 2024 - 2031
Figure 7. North America Prescription Drugs Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Branded: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 9. Generics: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 10. North America Prescription Drugs Market Share (%) - by Drug Type, 2024 and 2031
Figure 11. Small Molecule: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 12. Biologics and Biosimilar: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 13. North America Prescription Drugs Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 14. Oncology: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 15. Cardiovascular Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 16. Neurological Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 17. Metabolic Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 18. Respiratory Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 19. Immunology: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 20. Others: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 21. North America Prescription Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 22. Oral: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 23. Injectable: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 24. Topical: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 25. Others: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 26. North America Prescription Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 27. Hospital Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 28. Retail Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 29. Online Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 30. North America Prescription Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 31. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 32. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 33. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 34. Company Positioning & Concentration
Figure 1. North America Prescription Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. North America Prescription Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. North America Prescription Drugs Market Revenue (US$ Billion), 2024 - 2031
Figure 7. North America Prescription Drugs Market Share (%) - by Product Type, 2024 and 2031
Figure 8. Branded: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 9. Generics: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 10. North America Prescription Drugs Market Share (%) - by Drug Type, 2024 and 2031
Figure 11. Small Molecule: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 12. Biologics and Biosimilar: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 13. North America Prescription Drugs Market Share (%) - by Therapeutic Area, 2024 and 2031
Figure 14. Oncology: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 15. Cardiovascular Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 16. Neurological Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 17. Metabolic Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 18. Respiratory Diseases: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 19. Immunology: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 20. Others: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 21. North America Prescription Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 22. Oral: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 23. Injectable: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 24. Topical: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 25. Others: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 26. North America Prescription Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 27. Hospital Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 28. Retail Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 29. Online Pharmacies: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 30. North America Prescription Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 31. United States: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 32. Canada: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 33. Mexico: North America Prescription Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Billion)
Figure 34. Company Positioning & Concentration
